OBJECTIVES: To examine a population-based cohort for the association between clinicopathologic predictors of survival and immunohistochemical markers (IHC), and to assess changes in gene expression that are associated with lymphovascular invasion (LVI). SUMMARY BACKGROUND DATA: LVI has been associated with poor survival and aggressive tumor behavior. The molecular changes responsible for the behavior of gastric cancer have yet to be determined. Characterization of IHC markers and gene expression profiles may identify molecular alterations governing tumor behavior. METHODS: : Clinicopathologic and survival data of 114 patients were reviewed. Archival specimens were used to construct a multitumor tissue array that was subjected to IHC of selected protein targets. Correlation of IHC with tumor thickness (T status), LVI and prognosis was studied. Microarray analysis of fresh gastric cancer tissue was conducted to examine the gene expression profile with respect to LVI. RESULTS: In a multivariate analysis, nodal status (N), metastasis (M), and LVI were independent predictors of survival. LVI was associated with a 5-year survival of 13.9% versus 55.9% in patients in whom it was absent. LVI correlated with advancing T status (P = 0.001) and N status (P < 0.001). IHC staining of cyclooxygenase-2 (COX-2) correlated with T status, tumor grade, lymph node positivity, and IHC staining of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Microarray analyses suggested differential expression of oligophrenin-1 (OPHN1) and ribophorin-II (RPNII) with respect to LVI. CONCLUSION: LVI was an independent predictor of survival in gastric cancer. Expression of COX-2 may facilitate tumor invasion through MMP-2 and MMP-9 activation. OPHN1 and RPN II appeared to be differentially expressed in gastric cancers exhibiting LVI. The reported function of OPHN1 and RPN II makes these gene products promising candidates for future studies involving LVI in gastric cancer.
OBJECTIVES: To examine a population-based cohort for the association between clinicopathologic predictors of survival and immunohistochemical markers (IHC), and to assess changes in gene expression that are associated with lymphovascular invasion (LVI). SUMMARY BACKGROUND DATA: LVI has been associated with poor survival and aggressive tumor behavior. The molecular changes responsible for the behavior of gastric cancer have yet to be determined. Characterization of IHC markers and gene expression profiles may identify molecular alterations governing tumor behavior. METHODS: : Clinicopathologic and survival data of 114 patients were reviewed. Archival specimens were used to construct a multitumor tissue array that was subjected to IHC of selected protein targets. Correlation of IHC with tumor thickness (T status), LVI and prognosis was studied. Microarray analysis of fresh gastric cancer tissue was conducted to examine the gene expression profile with respect to LVI. RESULTS: In a multivariate analysis, nodal status (N), metastasis (M), and LVI were independent predictors of survival. LVI was associated with a 5-year survival of 13.9% versus 55.9% in patients in whom it was absent. LVI correlated with advancing T status (P = 0.001) and N status (P < 0.001). IHC staining of cyclooxygenase-2 (COX-2) correlated with T status, tumor grade, lymph node positivity, and IHC staining of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Microarray analyses suggested differential expression of oligophrenin-1 (OPHN1) and ribophorin-II (RPNII) with respect to LVI. CONCLUSION: LVI was an independent predictor of survival in gastric cancer. Expression of COX-2 may facilitate tumor invasion through MMP-2 and MMP-9 activation. OPHN1 and RPN II appeared to be differentially expressed in gastric cancers exhibiting LVI. The reported function of OPHN1 and RPN II makes these gene products promising candidates for future studies involving LVI in gastric cancer.
Authors: P Billuart; T Bienvenu; N Ronce; V des Portes; M C Vinet; R Zemni; H Roest Crollius; A Carrié; F Fauchereau; M Cherry; S Briault; B Hamel; J P Fryns; C Beldjord; A Kahn; C Moraine; J Chelly Journal: Nature Date: 1998-04-30 Impact factor: 49.962
Authors: Y Nakakubo; M Miyamoto; Y Cho; Y Hida; T Oshikiri; M Suzuoki; K Hiraoka; T Itoh; S Kondo; H Katoh Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640
Authors: Paulo R C Almeida; Francisco V A Ferreira; Cássio C Santos; Francisco D Rocha-Filho; Raul R R P Feitosa; Esther A A Falcão; Belise K Cavada; Roberto C P Lima-Júnior; Ronaldo A Ribeiro Journal: World J Gastroenterol Date: 2012-02-28 Impact factor: 5.742
Authors: Rahmatullah Rahmati; Snjezana Dogan; Owen Pyke; Frank Palmer; Mahmoud Awad; Nancy Lee; Dennis H Kraus; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Head Neck Date: 2014-06-19 Impact factor: 3.147
Authors: Michael F Nentwich; Katharina von Loga; Matthias Reeh; Faik G Uzunoglu; Andreas Marx; Jakob R Izbicki; Dean Bogoevski Journal: J Gastrointest Surg Date: 2013-10-04 Impact factor: 3.452